Popular Articles

USDA And HHS Praise Guidelines For Foodborne Disease Outbreak Response
Agriculture Secretary Tom Vilsack and Health and Human Services (HHS) Secretary Kathleen Sebelius commended the Council to Improve Foodborne Outbreak Response (CIFOR) for the new Guidelines for Foodborne Disease Outbreak Response. These guidelines assist local, state and federal agencies in preventing and managing foodborne disease outbreaks through planning, detection, investigation, control and prevention.
buy viagra
Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial
Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy.
News of the day
Premier Healthcare Alliance Acquires Phase 2 Consulting To Expand Its Performance Improvement Offerings To Its Member Hospitals Nationwide
The Premier healthcare alliance has acquired Phase 2 Consulting (P2C), a leading provider of consulting services to hospitals and health systems.
Sexual Health

Signature Genomic Laboratories Detects Chromosome Abnormalities In Individuals With Genetic Disorders Associated With Susceptibility To Cancer

Geneticists at Signature Genomic Laboratories recently demonstrated that microarray-based genetic testing can identify chromosome abnormalities that cause genetic disorders associated with susceptibility to cancer prior to the onset of symptoms. In their study, published in the May issue of Genetics in Medicine, geneticists from Signature reviewed data from 18,437 individuals who were tested by microarray analysis for unexplained mental retardation and congenital anomalies. DNA copy number gains or losses that encompassed gene regions associated with recognized genetic conditions with an increased risk for cancer were identified in 34 individuals. Almost three-quarters of those individuals had indications for study that were not specific to the diagnosed syndrome and therefore presumably did not have signs of cancer. The authors describe multiple instances in which early diagnosis improved medical management of the patient and allowed for early surveillance of cancer onset. "It is well known that microarray analysis allows for diagnosis of genetic syndromes at an early age that otherwise may not be diagnosed until onset of symptoms later in life," said Dr. Bassem A. Bejjani, M.D., Chief Medical Officer of Signature and senior author of the study. "However, this study shows the impact of early diagnosis is even more profound when a syndrome is associated with childhood-onset cancer, in which the threat of cancer is added to the child"s other medical issues." Signature Genomic Laboratories, LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):